Aidy Boothroyd reveals Parkinson's disease diagnosis
Aidy Boothroyd has revealed he has Parkinson's disease and that he tried to hide the condition for more than three years.
The 54-year-old said he had been diagnosed in November 2021, seven months after he quit as England Under-21 manager following five years in the role.
Former Watford manager Boothroyd, who has not coached since leaving Indian Super League side Jamshedpur in 2023, said he had been afraid to go public amid fears it would affect his career.
Boothroyd said he had been diagnosed during a visit to a neurologist after what he had expected to be a 'routine' League Managers Association (LMA) annual health assessment.
'I thought everything was fine,' he said. 'And then came the bombshell.
'I remember it well. It was raining, pouring. It was an awful day. And the guy said to me: 'This is a picture of a normal brain and this is the picture of your brain. You can see the difference. You've got Parkinson's. I'm very sorry'. So, I didn't know what to do. I didn't know what to say. I didn't really know what Parkinson's was.
'I just kept thinking about my kids. I just wasn't sure what was next. I was shocked. I was dumbstruck, really.
'I've kept very quiet about it. I wasn't ready to share with too many people. A handful of people knew.'
Boothroyd said the most noticeable symptom of his condition has been an inability to smile.
'In my case, probably the biggest one that I've noticed the most is facial masking. So, facial masking is when the dopamine in the brain can't always get to the body, and particularly in the facial muscles. So, my face could be, in my opinion, outwardly smiling, but actually it's not doing that at all.
'If I'm going for an interview, people will then ask me the questions and I'll look and I've had people say to me: 'Are you all right? Is everything OK, Aid? You're not your normal self.' So many people say, 'You're not your normal self. You're a bit quiet', which is all part of the Parkinson's.
'Nothing could be further from the truth. I'm enthusiastic, I'm excited. I still enjoy the job and working with people.'
Boothroyd went on: 'One of the biggest things I'd change would be to bring more people into my circle, because it can be tough when you're alone. I've chosen to not tell people because I was worried about it. I didn't want people to feel any less of what they thought of me before. So, that's been tough.
'I recently did London-to-Paris on the bike, with my friend Geoff Thomas. And I feel good. I feel fit. I know that the harder I work, the more physically I keep on top of myself, the harder it is for the Parkinson's to worsen.'
Boothroyd said his passion and love for coaching is 'as strong as ever' and that he was 'ready to start the next chapter in my life'.
'I'm not sure, whether, for me, I play a role as a No 2, where I'm there to support,' he said,
'There's a lot of things I think I can do. But something brand new might come out of it. I don't know. I just know that I've got decades of experience.
'I still am in love with the game, despite what my face says sometimes. And I'm privileged to be here, and I've still got a lot to give.
'I think my life's been on hold for three years and I've got a lot of people who want to help and support me, and I've got a lot of people I want to help and support as well.'
Boothroyd added: 'I was worried about how it might affect my chances of getting a job, a role, anywhere. It's been a burden. It's three years it's taken me to come to this position.
'I don't want to wallow. I don't want pity. What I want is to get back on the pitch, or wherever it is. But I won't let this define me.'
LMA chief executive Richard Bevan said: 'Aidy has displayed incredible positivity, resolve and determination since his Parkinson's diagnosis three years ago. His passion for football and people drives him on and he continues to play an active role in the LMA, as an almost ever-present senior member at our events and educational sessions.
'We care deeply for all our members, and Aidy's attitude since his diagnosis has been an inspiration to our entire team as we continue to support him and his family throughout this unexpected and challenging time.'
Parkinson's UK CEO Caroline Rassell said: 'Everyone at Parkinson's UK sends Aidy Boothroyd our best wishes and thanks him for raising awareness of Parkinson's by publicly sharing his diagnosis.
'With more than 40 symptoms, Parkinson's is unpredictable and undoubtedly introduces new challenges, but with the right support and staying active for 2.5 hours a week, people can take control of their lives.
'Aidy is now part of a community of 153,000 people in the UK who live with Parkinson's along with the millions of loved ones who support them. We are here to support them all.
'A public Parkinson's diagnosis often encourages people to think about their own health and we would encourage anyone concerned about symptoms to speak to their GP, visit parkinsons.org.uk or call the Parkinson's UK confidential helpline on 0808 800 0303.'
Former Plymouth, Southampton and Sheffield Wednesday manager Paul Sturrock revealed in 2008 that he had been diagnosed with Parkinson's eight years earlier. He is now 68.
Liverpool legend Ray Kennedy was diagnosed with early onset Parkinson's in 1984 at the age of 32. He died in 2021 aged 70.
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Gut bacteria changes may be warning sign for worsening Parkinson's
Changes in specific bacteria in the mouth and gut of patients with Parkinson's disease could potentially be an early warning sign that symptoms of the condition are getting worse, a study suggests. With the help of artificial intelligence (AI), scientists have linked these shifts to cognitive decline – problems with memory and learning – in people with the disease. They suggest the toxins could one day be used as 'markers' for medics to pinpoint the Parkinson's patients at a higher risk of dementia, as well as being used to help develop targeted treatments for the disease. Parkinson's disease is a progressive condition that affects the brain, with symptoms including involuntary shaking, known as tremors, as well as psychological problems such as depression, loss of balance, trouble sleeping and memory issues. According to the Alzheimer's Society, around a third of people with Parkinson's eventually develop dementia. 'The human gut and oral bacterial communities are increasingly linked to neurodegenerative diseases. Disruptions in the gut-brain axis could trigger inflammation and immune responses that contribute to neuronal damage," Dr Saeed Shoaie, group leader of the quantitative systems biology (QTS) lab at King's College London, said. "A common gum disease bacterium like porphyromonas gingivalis has been discovered as a potential driver of Alzheimer's." For the study, led by experts at King's College London and published in the journal Gut Microbes, scientists analysed 228 spit and stool samples. The samples came from 41 patients with Parkinson's and mild cognitive impairment, which causes problems with thinking and memory, 47 patients with Parkinson's and dementia and 26 healthy patients. The team found that the gut of people with mild cognitive impairment contained more harmful bacteria, many of which are likely to have come from the mouth. This bacteria releases toxins that can damage gut tissue, promote inflammation and potentially affect the brain, according to researchers. For a more in-depth analysis, the team used AI to pinpoint the bacterial species and functions not usually picked up by traditional testing, allowing them to link toxins specifically to cognitive decline. Dr Shoaie added: 'The emerging evidence underscores the potential importance of maintaining oral and gut health in mitigating or slowing neurodegenerative processes. 'As people with Parkinson's become increasingly reliant on carers, routine practices such as oral hygiene and nutritional intake may be neglected. 'Our findings suggest that promoting a healthy microbiome through consistent oral care, a balanced diet and potentially targeted probiotic interventions could support improved disease management in Parkinson's.'
Yahoo
7 hours ago
- Yahoo
Aspen Neuroscience to Present at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting
Presentation of Data from Clinical Trial of Aspen's Autologous iPSC-derived Approach for Neuronal Replacement Therapy in Parkinson's Disease SAN DIEGO, June 9, 2025 /PRNewswire/ -- Aspen Neuroscience, Inc. announced its participation in "Illuminating the Future," the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, to be held in Hong Kong June 11-14. Aspen Co-founder and Senior Vice President, Research and Development, Andrés Bratt-Leal, PhD will deliver a presentation, Safety, tolerability, and efficacy of transplanted autologous iPSC-derived dopaminergic precursors in moderate to advanced Parkinson's Disease. Dr. Bratt-Leal's presentation will cover data for the first four patients of the ASPIRO Study*, a Phase 1/2a trial of the company's iPSC-derived autologous cell therapy (ANPD001). The open label trial was designed to evaluate the safety, tolerability and efficacy of intracranial implantation of autologous induced pluripotent stem cell (iPSC)-derived dopaminergic neuronal precursor cells (DANPCs) in patients with moderate to advanced Parkinson's disease. The primary objective of the ongoing study is to assess safety and tolerability of the procedure. A secondary objective is to evaluate clinical efficacy as measured by change from baseline in multiple patient-reported and clinician-reported Parkinson's disease outcome measures. Continued follow up and evaluation of a higher-dose cohort in the study are ongoing. "Early data from the first four patients show that precision intracranial delivery of DANPCs is safe and well-tolerated," reported Dr. Bratt-Leal. "Both patient-reported and clinician-reported outcomes show early signs of changes from baseline in multiple clinically meaningful outcome measures. Autologous iPSC-derived therapy as a regenerative medicine approach has the unique advantage of not requiring immunosuppressive medications." About Aspen Neuroscience Headquartered in San Diego, Aspen Neuroscience, Inc. is a clinical development-stage, private company focused on autologous regenerative medicine. The company's patient-derived iPSC platform is used to create personalized therapies to address diseases with high unmet medical needs, beginning with autologous neuron replacement for PD. Aspen combines cell biology with the latest machine learning and genomic approaches to investigate patient-specific, restorative cell treatments. The company has developed a best-in-class platform to create and optimize pluripotent-derived cell therapies, which includes in-house bioinformatics, manufacturing and quality control. For more information and important updates, please visit or email media@ * The study was made possible by funding from the California Institute for Regenerative Medicine (CIRM), a state of California Agency that funds regenerative medicine, stem cell, and gene therapy research (Grant Number CLIN2-15547). View original content to download multimedia: SOURCE Aspen Neuroscience, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
21 hours ago
- New York Post
Simple tool could detect Parkinson's disease early — it was 96% accurate in experiments
This pen truly is mightier than the sword. A team of researchers at UCLA has developed a high-tech diagnostic pen that can detect signs of Parkinson's disease with over 96% accuracy, offering a low-cost way to identify the neurodegenerative disorder far earlier than now. A pilot study in the journal Nature Chemical Engineering unveiled the device, which looks much like a regular pen. 3 A patient with PD using the diagnostic pen for a writing task. Nature Chemical Engineering It's able pick up on subtle motor dysfunctions before they're visible to the naked eye, all by analyzing how people write. So, how does this futuristic fountain pen work? The tip is made of a flexible silicone material infused with magnetic particles, and it writes using a special ferrofluid ink that contains nanomagnets. As someone writes, pressure from the hand deforms the tip, causing changes in magnetic fields that produce electrical signals — like a Morse code of motor function. Those signals are then analyzed to detect the difference between healthy and Parkinson's-affected motor patterns. In tests with 16 participants — including 3 with Parkinson's — the system nailed the diagnosis with 96.22% accuracy. Even more impressive? The pen worked whether people wrote on paper or in the air, meaning it doesn't even require a surface. 3 Nature Chemical Engineering Today, Parkinson's is largely diagnosed based on observations, which are subjective, or by biomarker-based imaging, which can be expensive. This diagnostic pen is portable, inexpensive and doesn't rely on a neurologist to interpret results, making it a promising option for remote screenings, home use or even telehealth checkups. 'Our development of the diagnostic pen represents a low-cost, widely disseminable and reliable technology with the potential to improve PD diagnostics across large populations and resource-limited areas,' the researchers wrote. With further validation in a larger population, the device could be used not just for early diagnosis, but for ongoing symptom tracking and personalized treatment monitoring. 3 Today, Parkinson's is largely diagnosed based on observations, which are subjective, or by biomarker-based imaging, which can be expensive. highwaystarz – This is just the latest innovation aimed at tackling Parkinson's disease, which affects more than 10 million people worldwide and has no known cure. A recent study found that psilocybin — the psychedelic compound that gave 'magic mushrooms' their trippy reputation in the 1960s — showed serious promise for improving mood and motor function in people with Parkinson's disease. Tavapadon — a new drug that mimics dopamine by targeting certain receptors — has also shown promise in clinical trials by reducing motor fluctuations and maintaining symptom control with fewer side effects than traditional therapies. Produodopa — a continuous infusion therapy first administered in the UK — was approved by the US Food and Drug Administration last fall. Innovative approaches targeting the psychological aspects of the disease have been successful as well — with tandem cycling proving to be especially popular. Some New Yorkers even find relief by playing pingpong.
